COVID-19 News

Select COVID-19 and COVID-19 Vaccine Resources

• COVID-19 Vaccine Information Sources December 2020
• US Healthcare Professionals Information

From The CDC

• Information for Health Professionals

FDA - COVID - 19 - Notifications

• Latest Information
• Emergency Use Authorizations
• Food Safety

SBA Options

• Funding Relief Options
• Additional Loan Resources

CMS Resources

• CMS Adult Elective Surgery and Procedures Recommendations.

NIH COVID- 19 Information

• Latest Information

Health & Human Services Resources

• Policy Changes During the COVID-19 Public Health Emergency
• Providers: Billing & Reimbursement
• Providers: Legal Considerations
• Center for Connected Health Policy: Telehealth Policy

HOSS Resources & Announcements

• New England Journal of Medicine resources on the Coronavirus outbreak.
• COVID-19: Accelerated/Advance Payment, Find out more.
• COVID-19 Poses Special Challenges to Cancer Care, Find out more.
• OBR - No Pillow, No Paper: Oncology Practices Act Fast Against COVID-19, Find out more.
• Coronavirus 2019: What People with Cancer Need to Know, Find out more
• National Academies of Sciences, Engineering, Medicine list of science-based answers to the most commonly Googled questions about Coronavirus.

American Cancer Society Resources & Announcements

• American Cancer Society Cancer Action Network results of surveys on the effects of the pandemic on cancer patients and survivors, Find out more.
• Coronavirus, COVID-19, and Cancer Resources for Patients, Find out more.
• ACS Events Status, Find out more.

ASCO Resources & Announcements

• Coronavirus (COVID-19) Update: FDA Issues Guidance for Conducting Clinical Trials, Find out more.
• COVID-19 Clinical Oncology Frequently Asked Questions (FAQs), Find out more.
• ASCO Coronavirus Resources -  Click here for more.
• CORONAVIRUS and Centers for Medicare & Medicaid Services Actions
• ASCO advises oncologists to use the best available evidence in caring for patients who may be exposed to or infected with the novel coronavirus (COVID-19),  Click here for more.

ASH Resources & Announcements

• ASH COVID-19 Resources Page 
• COVID-19 Causes U.S. Lab Closures, Find out more.
• Emergency Guidance for Radiation Therapy to Continue Treating Patients with Hematologic Malignancies During Pandemic, Find out more.

COA Resources & Announcements

• COA Launches Practice Referral Service for Patients Seeking Cancer Treatment During Crisis, Find out more.
• COA COVID-19 Website, updated daily, Find out more.
• 2020 COMMUNITY ONCOLOGY CONFERENCE Virtual - April 23-24, 2020
• Prior Authorizations for Cancer Patients to Receive Treatment, Click here for more
• COA Resources - List serve, Click here for more.

NCCN Resources & Announcements

• NCCN Recommendations for the Use of Hematopoietic Growth Factors During COVID-19, Find out more.
• NCCN Coronavirus Disease 2019 (COVID-19) Resources for the Cancer Care Community, Find out more.

HOSS Industry News regarding COVID-19

• Agios Statement on COVID-19 and Prescribing Information for TIBSOVO, Find out more.
• AstraZeneca Video Platform for COVID-19 Patient Communications Now Available, Find out more.
• Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S., Find out more.
• Bristol Myers Squibb: A Message to Clinical Trial Investigators on Bristol Myers Squibb’s Response to COVID-19, Find out more.
• GSK Letter to Customers & Partners During the COVID-19 Pandemic, Find out more.
• Guardant Health Initiatives for Patient Care During COVID-19, Find out more.
• Johnson & Johnson: Seeking a diverse population for the Covid 19 vaccine trial called the EMSEMBLE study. Find out more here and here.
• Johnson & Johnson: Maintaining Continuity of Care During COVID-19,Find out more.
• Merck: Supporting Patients During the COVID-19 Pandemic, Find out more. Merck's Response to COVID-19, Find out more.
• Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak. Find out more.
• Pfizer is announcing preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target antigen for potential publication. Overall, the preliminary data demonstrated that BNT162b1 could be administered in a dose that was well tolerated and generated dose dependent immunogenicity, as measured by RBD-binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers. Find out more.
• Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program, Find out more
• Pfizer Information on products, patient assistance programs and medical information related to COVID-19, please click here.
• Pfizer Outlines Five-Point Plan to Battle COVID-19, Find out more.
• Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine, Find out more.
• Takeda Oncology will maintain continued support of patients and health care providers, Find out more.